Filtered By:
Condition: Thrombosis
Procedure: Heart Transplant

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 180 results found since Jan 2013.

Watchful Waiting in Continuous-Flow Left Ventricular Assist Device Patients With Ongoing Hemolysis Is Associated With an Increased Risk for Cerebrovascular Accident or Death Original Articles
Conclusions— Hemolysis refractory to intensification of antithrombotic therapy identifies continuous-flow left ventricular assist device patients at major risk for CVA and death. Early device exchange should be considered to minimize these risks.
Source: Circulation: Heart Failure - May 9, 2016 Category: Cardiology Authors: Levin, A. P., Saeed, O., Willey, J. Z., Levin, C. J., Fried, J. A., Patel, S. R., Sims, D. B., Nguyen, J. D., Shin, J. J., Topkara, V. K., Colombo, P. C., Goldstein, D. J., Naka, Y., Takayama, H., Uriel, N., Jorde, U. P. Tags: Cardiovascular Surgery, Transplantation, Cerebrovascular Disease/Stroke Original Articles Source Type: research

Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices Original Articles
Conclusions— INR is inversely related to thrombotic events occurring outside of the hospital among patients supported with CF-LVADs. INR values <2.0 increase the rate of thrombotic events occurring outside of the hospital among patients supported with CF-LVADs.
Source: Circulation: Heart Failure - May 5, 2016 Category: Cardiology Authors: Nassif, M. E., LaRue, S. J., Raymer, D. S., Novak, E., Vader, J. M., Ewald, G. A., Gage, B. F. Tags: Heart Failure, Anticoagulants, Transplantation, Intracranial Hemorrhage, Ischemic Stroke Original Articles Source Type: research

Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Publication date: Available online 10 March 2016 Source:Cell Author(s): Weifei Zhu, Jill C. Gregory, Elin Org, Jennifer A. Buffa, Nilaksh Gupta, Zeneng Wang, Lin Li, Xiaoming Fu, Yuping Wu, Margarete Mehrabian, R. Balfour Sartor, Thomas M. McIntyre, Roy L. Silverstein, W.H. Wilson Tang, Joseph A. DiDonato, J. Mark Brown, Aldons J. Lusis, Stanley L. Hazen Normal platelet function is critical to blood hemostasis and maintenance of a closed circulatory system. Heightened platelet reactivity, however, is associated with cardiometabolic diseases and enhanced potential for thrombotic events. We now ...
Source: Cell - March 12, 2016 Category: Cytology Source Type: research

HCV false positive immunoassays in patients with LVAD: a potential trap!
Over the last decades, left ventricular assist device (LVAD) has become the therapeutic choice for patients with advanced heart failure [1]. Patients benefit from a LVAD in different situations: as a bridge to cardiac transplantation or to recover a better heart function, or as a destination therapy [2]. The outcome of patients with LVAD has improved but it requires a close monitoring to avoid complications as bleeding, stroke, malignant arrhythmias, pump thrombosis and infection.
Source: Journal of Clinical Virology - March 10, 2016 Category: Virology Authors: Amélie Heinrichs, Martine Antoine, Deborah Steensels, Isabel Montesinos, Marie-Luce Delforge Tags: Short Communication Source Type: research

HeartWare plunges on uncertainty around its next-gen MVAD pump
Shares of HeartWare International (NSDQ:HTWR) are down some 28% today after the implantable heart pump maker said it can’t predict when it will be able to get its next-generation MVAD program back on line. Framingham, Mass.-based HeartWare said it expects to post sales of roughly $68 million for the 3 months ended Dec. 31, in line with the consensus forecast on Wall Street for $67.2 million. But the company said its still evaluating date from a CE Mark trial of the MVAD left ventricular assist device that was halted last fall, which it now says show evidence of blood clots in the pump. The incidence of pump thrombo...
Source: Mass Device - January 12, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices Clinical Trials Wall Street Beat HeartWare International Inc. Source Type: news

Mechanical circulatory support: balancing bleeding and clotting in high-risk patients.
Authors: Baumann Kreuziger L, Massicotte MP Abstract Mechanical circulatory support (MCS) provides a bridge to heart transplant in children and adults with life-threatening heart failure and sustains patients ineligible for transplant. Extracorporeal membrane oxygenation (ECMO) provides temporary support for patients in cardiac or pulmonary failure through external gas exchange and continuous flow of blood. Because the median time to heart transplant exceeds event-free time on ECMO, pulsatile left ventricular assist devices (LVADs) are used to support infants and children. Continuous flow LVADs are preferred in ado...
Source: Hematology ASH Education Program - December 10, 2015 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF A Multicenter Study
ConclusionsThe results show that the fully magnetically levitated centrifugal-flow chronic LVAS is safe, with high 30-day and 6-month survival rates, a favorable adverse event profile, and improved quality of life and functional status. (HeartMate 3™ CE Mark Clinical Investigation Plan [HM3 CE Mark]; NCT02170363)
Source: Journal of the American College of Cardiology - December 7, 2015 Category: Cardiology Source Type: research

Outcomes of ventricular assist device implantation in children and young adults: the Melbourne experience
ConclusionsChildren requiring pre‐transplant VAD support have a higher mortality and morbidity compared with young adults. Survival after heart transplantation those supported with VADs was similar to patients of similar age who did not require pre‐transplant support.
Source: ANZ Journal of Surgery - November 27, 2015 Category: Surgery Authors: William Y. Shi, Silvana F. Marasco, Pankaj Saxena, Yves d'Udekem, Matthew S. Yong, Sergei Mitnovetski, Christian P. Brizard, David C. McGiffin, Robert G. Weintraub, Igor E. Konstantinov Tags: Original Article Source Type: research

Short and long term outcomes of 200 patients supported by continuous-flow left ventricular assist devices.
CONCLUSION: Short and long term survival for patients on LVAD support are excellent, although outcomes still remain inferior compared to heart transplantation. The incidence of driveline infections, pump thrombosis and pump exchange have declined significantly in recent years. PMID: 26635927 [PubMed - as supplied by publisher]
Source: World Journal of Cardiology - November 26, 2015 Category: Cardiology Authors: Tsiouris A, Paone G, Nemeh HW, Borgi J, Williams CT, Lanfear DE, Morgan JA Tags: World J Cardiol Source Type: research

Low incidence of gastrointestinal bleeding and pump thrombosis in patients receiving the INCOR LVAD system in the long-term follow-up.
CONCLUSIONS: In this cohort of high-risk, advanced HF patients, the INCOR LVAD provided effective support with improved survival. Moreover, the absence of GI bleeding and pump thrombosis demonstrates a favorable characteristic of this device. Further prospective studies are needed to confirm these data. PMID: 26541278 [PubMed - as supplied by publisher]
Source: The International Journal of Artificial Organs - October 28, 2015 Category: Transplant Surgery Authors: Iacovoni A, Centofanti P, Attisani M, Verde A, Terzi A, Senni M, Maiani M, Baronetto A, Livi U, Frigerio M, Rinaldi M Tags: Int J Artif Organs Source Type: research

HeartWare completes enrollment in Endurance2 HVAD trial
HeartWare International (NSDQ:HTWR) said today it completed enrollment of its Endurance 2 destination therapy trial of its HeartWare ventricular assist system. The trial seeks to examine the rate of stroke in patients treated with HeartWare’s HVAD device as well as optimal blood pressure management, the company said. Data from the 465-patient supplemental cohort trial will be used to support pre-market approval for the HeartWare HVAD as a destination therapy system intended for long term use, according to the Framingham, Mass.-based company. The device is currently FDA approved for bridge-to-transplant applications....
Source: Mass Device - August 10, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Clinical Trials Regulatory/Compliance Surgical HeartWare International Inc. Source Type: news

The Subclavian Intraaortic Balloon Pump: A Compelling Bridge Device for Advanced Heart Failure
Conclusions The SC-IABP provided excellent hemodynamic support with minimal morbidity and mortality, allowed for extensive rehabilitation, and permitted more than 90% of patients to receive their intended therapy. Therefore, SC-IABP is a compelling bridge device for patients with advanced congestive heart failure.
Source: The Annals of Thoracic Surgery - July 28, 2015 Category: Cardiovascular & Thoracic Surgery Source Type: research

The Subclavian Intraaortic Balloon Pump: A Compelling Bridge Device for Advanced Heart Failure.
CONCLUSIONS: The SC-IABP provided excellent hemodynamic support with minimal morbidity and mortality, allowed for extensive rehabilitation, and permitted more than 90% of patients to receive their intended therapy. Therefore, SC-IABP is a compelling bridge device for patients with advanced congestive heart failure. PMID: 26228596 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - July 27, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Tanaka A, Tuladhar SM, Onsager D, Asfaw Z, Ota T, Juricek C, Lahart M, Lonchyna VA, Kim G, Fedson S, Sayer G, Uriel N, Jeevanandam V Tags: Ann Thorac Surg Source Type: research

How to define valvular atrial fibrillation?
Abstract Atrial fibrillation (AF) confers a substantial risk of stroke. Recent trials comparing vitamin K antagonists (VKAs) with non-vitamin K antagonist oral anticoagulants (NOACs) in AF were performed among patients with so-called "non-valvular" AF. The distinction between "valvular" and "non-valvular" AF remains a matter of debate. Currently, "valvular AF" refers to patients with mitral stenosis or artificial heart valves (and valve repair in North American guidelines only), and should be treated with VKAs. Valvular heart diseases, such as mitral regurgitation, aortic stenosis (AS) and aortic insufficiency, do...
Source: Archives of Cardiovascular Diseases - July 13, 2015 Category: Cardiology Authors: Fauchier L, Philippart R, Clementy N, Bourguignon T, Angoulvant D, Ivanes F, Babuty D, Bernard A Tags: Arch Cardiovasc Dis Source Type: research

Impact of Renal Impairment on Cardiovascular Disease Mortality After Liver Transplantation for Nonalcoholic Steatohepatitis Cirrhosis
ConclusionNASH recipients have an increased risk of CVD mortality after liver transplantation explained by a high prevalence of co‐morbid cardiometabolic risk factors that in aggregate identify those at highest risk of post‐transplant CVD mortality.This article is protected by copyright. All rights reserved.
Source: Liver International - May 15, 2015 Category: Gastroenterology Authors: Lisa B. VanWagner, Brittany Lapin, Anton I. Skaro, Donald M. Lloyd‐Jones, Mary E. Rinella Tags: Original Article Source Type: research